NCT00026884 Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
| NCT ID | NCT00026884 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Cancer Institute (NCI) |
| Condition | Malignant Neoplasms |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,950 participants |
| Start Date | 1998-03-12 |
| Primary Completion | — |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,950 participants in total. It began in 1998-03-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Selected individuals suspected of having or with prior biopsy proof of malignant disease will be seen in the Urologic Oncology Branch, NCI. Blood samples may be collected at the time of the initial visit and at periodic intervals during the course of the disease. These samples will be stored in the tissue bank of the Urologic Oncology Branch. Aliquots of malignant and normal tissue will be collected at the time of surgery and stored in the tissue bank, Urologic Oncology Branch, NCI. These materials will be used in the research efforts of the Urologic Oncology Branch, NCI.
Eligibility Criteria
* INCLUSION CRITERIA: * Individuals with biopsy-proven malignant disease * Individuals suspected of having a malignant disease * Individuals who have or are suspected of having an inherited genitourinary malignant disorder * Participants must be \>= 2 years of age * A relative (related by blood) of an individual with a confirmed or suspected diagnosis of a malignant disease or an inherited genitourinary malignant disorder. * All participants and parents/guardians, for children younger than 18 years of age, must sign an informed consent document indicating their understanding of the investigational nature and the risks of this study before any protocol related studies are performed. EXCLUSION CRITERIA: -Individuals whose co-morbidities preclude surgical intervention.
Contact & Investigator
W. Marston Linehan, M.D.
PRINCIPAL INVESTIGATOR
National Cancer Institute (NCI)
Frequently Asked Questions
Who can join the NCT00026884 clinical trial?
This trial is open to participants of all sexes, aged 2 Years or older, studying Malignant Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT00026884 currently recruiting?
Yes, NCT00026884 is actively recruiting participants. Contact the research team at deborah.nielsen@nih.gov for enrollment information.
Where is the NCT00026884 trial being conducted?
This trial is being conducted at Bethesda, United States.
Who is sponsoring the NCT00026884 clinical trial?
NCT00026884 is sponsored by National Cancer Institute (NCI). The principal investigator is W. Marston Linehan, M.D. at National Cancer Institute (NCI). The trial plans to enroll 5,950 participants.